Compare MRTN & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRTN | MPLT |
|---|---|---|
| Founded | 1946 | 2018 |
| Country | United States | United States |
| Employees | N/A | 133 |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 1994 | N/A |
| Metric | MRTN | MPLT |
|---|---|---|
| Price | $17.34 | $27.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $32.67 |
| AVG Volume (30 Days) | ★ 790.3K | 272.0K |
| Earning Date | 04-23-2026 | 05-28-2026 |
| Dividend Yield | ★ 1.61% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $1,131,455,000.00 | N/A |
| Revenue This Year | $2.23 | N/A |
| Revenue Next Year | $8.59 | N/A |
| P/E Ratio | $888.50 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.35 | $12.24 |
| 52 Week High | $18.48 | $33.28 |
| Indicator | MRTN | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 55.69 | 45.70 |
| Support Level | $14.31 | $26.07 |
| Resistance Level | $18.48 | $31.69 |
| Average True Range (ATR) | 0.50 | 2.43 |
| MACD | -0.10 | -0.26 |
| Stochastic Oscillator | 25.16 | 26.24 |
Marten Transport Ltd is a temperature-sensitive and dry truckload carrier in the United States. The company specializes in transporting and distributing food and other consumer packaged goods that require a temperature-controlled or insulated environment. The company operates through four segments: Truckload, Dedicated, Intermodal, and Brokerage, generating the majority of its revenue from the Truckload segment. The Truckload segment offers a mix of regional short-haul and medium- to long-haul full-load transportation services transporting food and other consumer packaged goods.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.